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ABSTRACT
Background: FKBP51 is a co-chaperone with isomerase activity, abundantly 
expressed in glioma. We previously identified a spliced isoform (FKBP51s) and 
highlighted a role for this protein in the upregulation of Programmed Death Ligand 
1 (PD-L1) expression in melanoma. Because gliomas can express PD-L1 causing 
a defective host anti-tumoral immunity, we investigated whether FKBP51s was 
expressed in glioma and played a role in PD-L1 regulation in this tumour.
Methods: We used D54 and U251 glioblastoma cell lines that constitutively 
expressed PD-L1. FKBP51s was measured by immunoblot, flow cytometry and 
microscopy. In patient tumours, IHC and qPCR were used to measure protein and 
mRNA levels respectively. FKBP51s depletion was achieved by siRNAs, and its 
enzymatic function was inhibited using selective inhibitors (SAFit). We investigated 
protein maturation using N-glycosidase and cell fractionation approaches.
Results: FKBP51s was expressed at high levels in glioma cells. Glycosylated-PD-L1 
was increased and reduced by FKBP51s overexpression or silencing, respectively. 
Naïve PD-L1 was found in the endoplasmic reticulum (ER) of glioma cells complexed 
with FKBP51s, whereas the glycosylated form was measured in the Golgi apparatus. 
SAFit reduced PD-L1 levels (constitutively expressed and ionizing radiation-induced). 
SAFit reduced cell death of PBMC co-cultured with glioma.
Conclusions: Here we addressed the mechanism of post-translational regulation 
of PD-L1 protein in glioma. FKBP51s upregulated PD-L1 expression on the plasma 
membrane by catalysing the protein folding required for subsequent glycosylation. 
Inhibition of FKBP51s isomerase activity by SAFit decreased PD-L1 levels. These 
findings suggest that FKBP51s is a potential target of immunomodulatory strategies 
for glioblastoma treatment.
INTRODUCTION
Glioblastoma is the most dangerous and aggressive 
form of brain cancer. Currently, the curative attempt 
is not possible in the majority of glioblastoma patients. 
However, there are some long-term survivors. The 
use of targeting molecules that neutralize the so-
called “checkpoint inhibitors” of the immune system 
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is a promising strategy for glioblastoma treatment [1]. 
Similarly to many other tumours, gliomas express 
Programmed Cell Death-Ligand 1 (PD-L1) [2–4], 
encoded by the PDCD1L1 gene. Although PD-L1 is not 
an oncogenic driver of the tumour per se, it nevertheless 
protects the tumour from its immune microenvironment. 
Engagement of PD-L1, with its cognate receptor PD1, 
expressed by activated lymphocytes, inhibits T-cell 
activation via phosphatase SHP2-mediated inhibition 
of kinases [5]. PD-L1 can also exert an inhibitory effect 
on T cells through B7-1 [6]. Monoclonal antibodies 
targeting PD-1/PD-L1 are being extensively used in a 
wide range of solid tumour types, including melanoma, 
non-small cell lung cancer, squamous cell cancer of head 
and neck, bladder cancer, renal cell carcinoma, as well 
as haematological malignancies, particularly, aggressive 
B-cell lymphomas and multiple myeloma [7]. The 
predictive value of PD-L1 as a biomarker of response is 
under continuous investigation, especially because of the 
numerous technical issues associated with IHC. The use of 
various PD-L1 antibodies and diverse IHC cut-offs across 
clinical trials has made it difficult to assess the usefulness 
of PD-L1 as a biomarker of response. However, some 
available data suggest that patients with higher levels 
of PD-L1 expression have an improved response rate to 
immunotherapy and progression-free survival [8]. PD-
L1 expression in glioblastoma tumours is considerably 
higher than that observed in melanoma and lung cancer 
[3]. Also, PD-L1 expression in glioma is sustained and 
increased by standard radiation treatments [9, 10]. Based 
on their encouraging efficacy in an increasing variety of 
human neoplasias, several clinical studies are currently 
under way to evaluate checkpoint inhibitors in patients 
with glioblastoma [11–13]. A major concern of the 
immune checkpoint blockade remains immunotoxicity, 
with related adverse events that are sometimes life-
threatening and prevent the completion of the treatment. In 
addition, the occurrence of primary or acquired resistance 
to the inhibitory immune checkpoint-targeted therapy 
represents a further limitation of this anti-cancer approach. 
A better understanding of the specific mechanisms 
that regulate PD-L1 expression may provide new tools 
for circumventing the tumour’s ability to suppress its 
immune microenvironment. Parsa et al. demonstrated the 
dependence of PD-L1 expression on the PI3k/Akt pathway 
in human glioma and showed a post-transcriptional 
increase of such immune-inhibitory ligands after the 
loss of PTEN [14]. Similarly to several other membrane 
proteins, PD-L1 expression is also regulated at a post-
translational level. PD-L1 undergoes heavy glycosylation 
that greatly increases the affinity for PD1 [15]. The 
targeting of mechanisms that control post-translational 
modification can help in neutralizing the pro-tumoral 
effect of PD-L1. Our research has previously identified 
a role for a spliced variant of the FKBP5 gene in the 
regulation of PD-L1 expression in melanoma [16]. FKBP5 
encodes a large immunophilin which was originally cloned 
in lymphocytes [17] but also found abundantly expressed 
in several tumours [18–23], including glioblastoma [24]. 
The FKBP51 protein structure includes a C-terminal TPR 
three tandem repeat domain, responsible for protein-
protein interaction, and two N-terminal FK506 binding 
domains (FKBP), of which the most N-terminal one 
exerts a peptidyl-prolyl isomerase (PPIase) activity [25]. 
The spliced isoform (isoform 2 or FKBP51s) [16] lacks 
a TPR domain and has a distinct C-terminus compared 
to isoform 1. Isoform 2 resulted induced, bidirectionally, 
in melanoma and lymphocytes following their interaction 
through the PD-L1/PD1 ligand/receptor system [16]. 
Classically, the PPIase activity of FKBPs is inhibited by 
the immunosuppressant agents rapamycin and FK506. 
More recently, potent and specific inhibitors of FKBP51 
have been created and named SAFit 1 and 2 because of 
their selectivity through an “induced fit” mechanism [26]. 
Here we aimed to investigate the role of FKBP51s in 
PD-L1 regulation in glioma. FKBP51s showed varying 
degrees of expression in glioma cancer cell lines and 
tumours from patients. Silencing of FKBP51s reduced the 
expression levels of glycosylated PD-L1 forms. FKBP51s 
physically interacted with the naïve PD-L1 protein in 
the endoplasmic reticulum (ER), suggesting it served 
as a catalyst of PD-L1 glycosylation. We also show that 
SAFit1 and, especially, SAFit2 reduced expression of PD-
L1 and impaired ionizing radiation (IR)-induced PD-L1 
up-regulation.
RESULTS
Expression of FKBP51s in glioma cells
We measured the expression of FKBP51 isoforms 
by immunoblot in D54 and U251 glioma cells, using 
A375 and SAN melanoma cell lines for comparison. 
As shown in Figure 1A, both the canonical and the 
spliced FKBP51 isoforms were expressed in the 
glioblastoma cells. Whereas in melanoma, FKBP51s 
was barely detected under basal conditions [16]. 
FKBP51s expression in glioblastoma cells was 
confirmed by fluorescent microscopy (Figure 1B), 
showing a localization in both nuclear and cytoplasmic 
compartments (Figure 1B). A co-staining of both 
isoforms showed that the canonical and the spliced 
FKBP51 are coexpressed, even if the canonical isoform 
seems to have a brighter nuclear signal than the short 
isoform (Figure 1C). The co-staining also suggested 
that, in some glioma cells, the short isoform appears 
as the only detectable form in the nucleus. Figure 1C 
also suggests the specificity of the FKBP51s signal, 
as it was barely detectable in another cell line (iPSCs, 
undifferentiated human induced Pluripotent Stem Cell) 
that was found to express the canonical isoform.
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FKBP51s regulates PD-L1 expression
To investigate the role of FKBP51s on PD-L1 
expression regulation in glioma, we first measured PD-L1 
levels in U251 and D54 glioblastoma cell lines by flow 
cytometry (Figure 2A) and immunoblot (Figure 2B). Both 
cell lines expressed high levels of PD-L1 on the plasma 
membrane (Figure 2A). Several PD-L1 isoforms were 
observed by immunoblot (Figure 2B). A lower band (at 
~37 kDa) corresponding to the naïve protein and two 
upper bands at ~50 and ~68 kDa could be accounted for by 
post-translationally modified isoforms [15, 16]. However, 
as other authors and we noted [32], PD-L1 expression 
has a highly variable pattern and banding, even using the 
same antibody for detection. Such variability is mostly 
because of post-translationally modified forms or different 
degrees of protein maturation [32]. Consistently, in our 
study, additional bands between 37–50 kDa or under 37 
kDa were sometimes detected. Next, we used different 
FKBP51s siRNAs and a PD-L1 siRNA for protein 
knockdown and evaluated modulation of PD-L1 levels by 
immunoblot. Figure 2C shows that both FKBP51s siRNAs 
#1 and #2 (but especially the siRNA #2 and the siRNA 
combination) were effective at reducing PD-L1 levels in 
U251 glioma cells. The intensity of the 68-kDa band was 
reduced with both FKBP51s siRNA and PD-L1 siRNA. 
The 50-kDa band was reduced when cells were treated 
with FKBP51s siRNAs and especially the mix of siRNAs, 
which strongly reduced FKBP51s levels. A decrease of the 
37 kDa PD-L1 band was observed with PD-L1 siRNA and, 
surprisingly, also under FKBP51s silencing. The level of 
the PD-L1 transcript of U251 and D54 cells was reduced 
by PD-L1 siRNA but not FKBP51s silencing (under the 
latter condition, PD-L1 transcript appeared to be slightly 
increased) (Supplementary Figure 1). Apparently, this 
result excluded a transcriptional regulation by FKBP51s 
and, thus, the decrease in the band at 37 kDa could reflect 
a condition of ER stress related to possible imbalance 
of ER-proteins. The observation that intensity of the 
highest kDa bands was reduced by FKBP51s siRNA more 
than PD-L1 siRNA was consistent with our hypothesis 
that FKBP51s is involved in PD-L1 post-translational 
control. The effect of FKBP51s knockdown on PD-L1 
was also evaluated by flow cytometry. Analysis of mean 
fluorescence intensities (MFI) of PD-L1 expression on the 
plasma membrane of U251 cells suggested a significant 
decrease in PD-L1 expression following FKBP51s 
silencing (Figure 2D). Representative PD-L1 histograms 
in the overlay, from U251 cells, are shown in Figure 2E. 
Finally, to confirm that FKBP51s positively regulated PD-
L1 expression in glioma, we overexpressed this FKBP51 
isoform in D54 and U251 cells and measured PD-L1 
level by immunoblotting. Figure 2F shows that the ~50 
and 68 kDa PD-L1 bands were increased by FKBP51s-
overexpression compared to control cells transfected with 
empty vector. Supplementary Figure 1B shows the mRNA 
levels of PD-L1 and FKBP51s in transfected D54 and 
U251 cells.
FKBP51s serves as a PD-L1 co-chaperone in ER
The addition of carbohydrates is the principal 
chemical modification to most plasma membrane proteins. 
PD-L1 is N-glycosylated (http://www.uniprot.org/uniprot/
Figure 1: FKBP51s expression in glioma cells. (A) Immunoblot assay of FKBP51 and FKBP51s expression in D54 and U251 
glioma cell lines. Lysates from A375 and SAN melanoma cell lines were run for comparison. γ-Tubulin was used as loading control. (B) 
FKBP51s (green) immunostaining of D54 and U251. DAPI (blue) was used to counterstain nuclei; FKBP51s/DAPI merge was shown. 
Scale bar 50μm. Image was captured with an inverted microscope (DMI4000; Leica Microsystems, Heidelberg, Germany) and Leica 
Application Suite Advanced Fluorescence (LAS AF) software (Leica Microsystems). (C) D54 glioma cell and the undifferentiated human 
iPSC were stained with DAPI (blue) to counterstain nuclei; FKBP51 (red); FKBP51s (green); FKBP51/FKBP51s merge was shown. Scale 
bar 50μm. Confocal images were captured with Leica TCSSMD FLIM (Leica Microsystems) microscopes.
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Q9NZQ7#ptm_processing). Because glycosylation can 
occur in the lumen of the ER and/or in the lumina of the 
Golgi cisternae, to address the role of FKBP51s in PD-
L1 glycosylation, we performed subcellular fractionation 
of D54 cells and obtained protein extracts from these cell 
compartments. As shown in Figure 3A, the naïve 37 kDa 
PD-L1 was detectable in the ER, and scarcely in the Golgi. 
The 68-kDa band was expressed mostly in the Golgi. 
In the Golgi, the band at 50 kDa was also appreciable. 
FKBP51s, but not FKBP51, was found in the ER. The 
naïve PD-L1, FKBP51 and FKBP51s were all found in the 
nucleus. By using an N-glycosidase, we could confirm that 
the 68-kDa band was glycosylated. As shown in Figure 
3B (right), treatment of the immunoprecipitated PD-L1 
protein with PNGase F produced a decrease of the 68-kDa 
band (indicated by the right arrow) and the appearance 
of an additional band at around 37 kDa (indicated by the 
left arrow). These findings suggest that FKBP51s has 
a role in catalysing PD-L1 folding, an essential step of 
glycosylation. To address this issue, we performed co-IP 
of protein from purified ER extract. As shown in Figure 
3C, pull-down of either FKBP51s or PD-L1 confirmed 
that the two proteins interact with each other in the ER.
SAFits, the selective inhibitors of FKBP51, 
reduce PD-L1 expression
Because SAFit compounds selectively inhibit the 
catalytic activity of FKBP51, we investigated their ability 
to modulate expression of PD-L1 in glioma cells. Figure 
4A shows a dose response assay of PD-L1 expression 
levels, measured by flow cytometry, after 12 h of culture 
Figure 2: Modulation of PD-L1 expression in glioblastoma cells. (A) Flow cytometric histograms of PD-L1 expression in U251 
and D54 glioblastoma cells. (B) Immunoblot of lysates prepared from the same cells shows 3 isoforms ascribable to the naïve (37 kDa) 
and post-translational modified protein (~50 and ~68 kDa). (C) Immunoblot of cell lysates obtained from the glioblastoma cell line U251, 
transfected with FKBP51s siRNAs, PD-L1 siRNA or a non-silencing (NS) RNA. G3PDH was used as loading control. (D) U251 cells 
treated as in C, was analysed by flow cytometry for PD-L1 expression. The graph represents MFI (mean and standard deviation) of PD-L1 
expression. P values are indicated (N=6). (E) Flow cytometric histograms of PD-L1 expression in U251 glioma cells, silenced or not for 
FKBP51s, or PD-L1. Histograms are shown in overlay. (F) Immunoblot of cell lysates obtained from the D54 and U251 glioblastoma cell 
lines over expressing FKBP51s or transfected with the void vector (EV). Expression of PD-L1 resulted increased by FKBP51s but not EV 
transfection. γ-Tubulin was used as loading control.
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Figure 3: FKBP51s is associated with PD-L1 in ER. (A) Immunoblot of D54 lysates obtained from sub-cellular compartments. 
PD-L1, FKBP51 and FKBP51s levels are shown along with relative organelle markers. (B) Whole D54 lysates immunoprecipitated with 
anti-PD-L1 and subjected, or not, to PNGase F treatment; the arrows indicate the higher (- PNGase F) and lower (+ PNGase F) PD-L1 band. 
Fetuin, on the left of the panel, was used as positive control of PNGase digestion. (C) Co-IP of PD-L1 and FKBP51s in ER fraction. ER 
lysate was immunoprecipitated with anti-PD-L1 and anti-FKBP51s and recognized for each protein by immunoblot.
Figure 4: SAFit reduces the expression of PD-L1. (A) Dose response assay of SAFit on PD-L1 expression. D54 glioblastoma cells 
were incubated with SAFit1 and 2 at different concentrations. After 12 h of incubation, cells were harvested and analysed by flow cytometry 
for PD-L1 expression. Graph columns represent mean fluorescence intensities and bars the standard deviation of PD-L1 expression (N=3). 
(B) Kinetic of PD-L1 expression. Glioblastoma cells were incubated with SAFit2 at different times, then, cells were harvested and analysed 
by flow cytometry for PD-L1 expression. Graph represents mean fluorescence intensities of PD-L1 expression (N=3). (C) Flow cytometry 
(left) and immunoblot (right) of SAFit-modulated PD-L1 expression. Cells were cultured, in the absence or the presence of 50 nM SAFit2 
for 12h. (D) Dose response assay of IR-induced PD-L1 expression and modulation by SAFit2. D54 glioblastoma cells were irradiated at 
different Gy doses (1, 4 and 8Gy), in the absence or the presence of 50 nM SAFit2. After 12 h incubation, cells were harvested and analysed 
by flow cytometry for PD-L1 expression. The graph represents mean fluorescence intensities (mean and standard deviation, N=3) of PD-L1 
expression. (E) Kinetic of IR-induced PD-L1 expression levels. D54 cells were harvested 3, 12 and 24h after 4 Gy IR. The band at 68 kDa 
(indicated by the arrow) resulted increased after 12 and 24 h from IR. The addition of SAFit prevented such an increase. (F) Immunoblot 
of lysates obtained from sub-cellular compartments of D54 cells after a 4 Gy IR. PD-L1 and FKBP51s levels are shown along with relative 
organelle markers. (G) Immunoblot of D54 lysates obtained from sub-cellular compartments. D54 cells cultured in the presence or not of 
SAFit2, was harvested 12h after IR. PD-L1 is shown along with relative organelle markers. SAFit2 reduced ER and Golgi PD-L1 bands. 
(H) pAkt expression levels in D54 lysates obtained from whole cell and ER compartment, shown along with ER marker.
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in the presence of one of three doses of SAFit1 and SAFit2 
(5, 25 or 50 nM). Both compounds (but especially SAFit2) 
produced a decrease in PD-L1 expression on the plasma 
membrane, as measured by flow cytometry. SAFit2 
significantly inhibited PD-L1 activity at 12 h, but activity 
returned to the baseline after 48 h (Figure 4B). Figure 4C 
shows a representative flow cytometry histogram of PD-
L1 down modulation by SAFit2 (left) and an immunoblot 
(right) showing that the post-translational modified forms 
of PD-L1 (indicated by the arrows) are especially affected 
by SAFit2. Because ionizing radiation increases tumour 
cell expression of PD-L1 [10], we investigated whether 
SAFit was able to counteract such an IR effect. Using 
different IR doses, we detected a significant increase in 
PD-L1 expression at 4 and 8 Gy (p=0.05), compared with 
non-irradiated glioma cells (Figure 4D). Upregulation of 
PD-L1 after IR was also measured at the mRNA level 
(Supplementary Figure 2). SAFit2 produced a decrease 
in PD-L1 expression. In the presence of SAFit2, PD-L1 
expression following 4 Gy irradiation was similar to the 
untreated control cells (Figure 4D). An immunoblot of 
D54 cell extracts prepared at 0, 3, 12 and 24 h following 
irradiation showed an increase of the intensity of the 
band at 68 kDa (indicated by the arrow) after 12 and 24 h 
(Figure 4E). Such an increase appeared to be counteracted 
by SAFit2 (Figure 4E). The blot also shows two bands of 
around 37 kDa. The lower of these bands was especially 
induced at 12 h after irradiation. This approximately 
34-kDa band might correspond to a cleavage product 
or further isoform of PD-L1, which is increased by IR. 
The blot also shows a decrease of the 37 kDa band after 
24 h of SAFit plus IR, which suggests that SAFit might 
affect protein synthesis. Analysis of extracts obtained by 
cell fractionation (Figure 4F) shows that, in the ER, IR 
induces the expression of PD-L1 forms of between 37 
and 50 kDa (at 12 h after irradiation) but that these are 
decreased at 24 h. Interestingly, FKBP51s disappeared 
from the ER at 3 h after IR, reappearing at 12 h after IR. 
Golgi extracts showed that the levels of the PD-L1 upper 
band changed in accordance with the upper band of whole 
extracts. To address the effect of SAFit on IR-induced 
PD-L1 upregulation, we irradiated the cells in the absence 
or the presence of 50 nM SAFit2 and recovered extracts 
after 12 h. By this approach, we confirmed that IR induces 
the expression of PD-L1 forms of up to 37 kDa and that 
this effect is attenuated by SAFit2 (Figure 4G). The role 
of FKBP51s in IR-induced PD-L1 increase was further 
investigated using a siRNA for FKBP51s in irradiated 
cells. As shown in Supplementary Figure 3, FKBP51s 
silencing impaired IR-induced PD-L1 upregulation.
In addition, we thought to investigate the levels of 
pAkt during IR, given that Akt is the master regulator of 
PD-L1 expression in glioma [11]. Phospho-Akt levels 
were increased at 3 h after IR, remained high at 12 h 
after IR, and decreased at 24 h after IR (Figure 4H). An 
analysis of pAkt levels in ER extracts found that these 
levels were particularly high in this cell compartment 
(Figure 4H), which is consistent with the role of Akt in 
the ER membrane [33]. The observation that the PD-L1 
maturation forms appeared in the ER only upon restoration 
of the FKBP51s level, is a further element in support of 
the important FKBP51s function as a PD-L1 molecular 
chaperone in ER.
SAFits reduce PD-L1-induced cell death of 
PBMC cocultured with glioma cells
The PD1 receptor was identified as a gene 
upregulated in a T-cell hybridoma undergoing cell death 
[34]. Accordingly, triggering PD1 through PD-L1 induces 
cell death [35]. We performed co-cultures of glioblastoma 
and healthy donor PBMCs, as previously described [16], to 
address whether SAFit-mediated PD-L1 down modulation 
on glioma cells could modulate death of PBMC via 
tumour-associated PD-L1. To this end, we used different 
glioma cell lines, D54, U251 and SF767, the latter of 
which expresses very low levels of PD-L1 (Figure 5A) 
and performed PBMC/glioma co-cultures. PBMCs were 
harvested after 6 h and analysed by annexin V staining 
in double fluorescence with CD45, by flow cytometry. A 
gate was placed on CD45 positive cells to exclude non-
PBMC cells from the analysis (Supplementary Figure 4). 
Figure 5B shows box plots of cell death values of PBMC 
not co-cultured (no CC) or co-cultured with glioma cells 
(CC). We measured a significant increase in the cell death 
of PBMCs co-cultured with glioma cells, compared to 
cell death of no CC PBMCs. The addition of anti-PD1, 
but not an unrelated humanized antibody (abciximab) 
[27], reduced cell death in D54 and U251 but not in 
SF767 co-cultures (Figure 5B). These results suggest that 
glioma cells can kill PBMCs through PD-L1. However, 
the observation that CC/SF767 PBMC also undergoes cell 
death suggests a tumoral-induced cytotoxicity independent 
of PD-L1, possibly involving other factors (e.g. Fas 
ligand [36] or TGF-β [37]). A further detailed analysis for 
comparison of apoptosis of each experimental condition 
is shown in Supplementary Table 1. Use of SAFit1 and 
SAFit2 also resulted in protection of CC/D54- and CC/
U251-PBMC from cell death, in accordance with the PD-
L1 down modulation effect by SAFit. Additionally, the use 
of PD-L1 siRNA, to down modulate PD-L1 on glioma cell 
lines, reduced CD45+ cell death in D54- and U251- but 
not SF767- co-cultures (Figure 5C), thus supporting the 
causative role of PD-L1 in glioma killing of immune cells.
FKBP51s is expressed in glioblastoma specimens 
from patients
Expression of FKBP51s and PD-L1 was investigated 
by immunohistochemistry in 29 glioblastoma specimens. 
Details on IHC semi quantitative evaluation are reported 
in Supplementary Table 2. PD-L1 staining was observed 
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in glioblastoma tissues to a variable extent and intensity. 
In the majority of the cases, 22/29 (75.86%), a prominent 
cytoplasmic diffuse/fibrillary expression pattern was 
observed. In 3 of these 22 cases (3/29; 10.34%), we found 
interspersed singular or focally aggregated epithelioid 
cells, with membranous immunostaining for PD-L1. 
Very faint and focal immunoreactivity was observed in 
perilesional brain tissue, when present. In Figure 6A, 6B 
and 6C, hematoxylin and eosin staining, expression of 
the glial fibrillary acidic protein and PD-L1 expression 
of case #28 are shown. Two further PD-L1 IHC results 
are shown in Supplementary Figure 5. Cytoplasmic and 
nuclear FKBP51s expressions of tumour tissue were 
observed (Figure 6D–6F). Both of these were scored. The 
semi quantitative distribution of cytoplasmic FKBP51s 
was as follows: score 0 in 10 of 29 cases (35%), score 
1 in 6 of 29 cases (21%), score 2 in 1 of 29 cases (3%), 
score 3 in 5 of 29 cases (18%), score 4 in 3 of 29 cases 
(10%), score 6 in 3 of 29 cases (10%) and score 9 in 1 
of 29 cases (3%). Nuclear FKBP51s scores were 0 in 2 
of 29 cases (7%), score 1 in 3 of 29 cases (10%), score 
2 in 8 of 29 cases (28%), score 3 in 1 of 29 cases (3%), 
score 4 in 6 of 29 cases (21%), score 6 in 6 of 29 cases 
(21%), score 9 in 3 of 29 cases (10%). Statistical analysis 
revealed that the scores of FKBP51s were different when 
comparing specimens with absent/low-PD-L1 (arbitrarily 
defined as a score >=0, <=3) and high-PD-L1 (score >=4, 
<=9). As shown in Figure 6G, the levels of FKBP51s, both 
cytoplasmic and nuclear, are likely to be increased in high-
PD-L1 samples, which is in line with in vitro findings that 
FKBP51s drives PD-L1 expression. FKBP51s expression 
was confirmed at the mRNA level in eight glioblastoma 
specimens (Figure 6H).
DISCUSSION
Here, we address the expression and function 
in glioma of FKBP51s [10], a protein isoform that is 
generated by an alternative splicing of the FKBP5 gene. 
FKBP51s was first identified in melanoma [16]. Unlike in 
Figure 5: PD-L1-induced PBMC death is reduced by SAFit. (A) PD-L1 expression in D54, U251 and SF767 glioblastoma cells 
analysed by flow cytometry (upper) and immunoblot (lower). (B) Graphical representation of cell death values of PBMC not cocultured 
(no CC) or cocultured (CC/) for 6 h with D54, U251 and SF767 glioblastoma cells, in the absence or presence of anti-PD1, SAFit1, 
SAFit2 or a humanized antibody (abciximab) as control. PBMC was harvested and assayed in flow cytometry for Annexin-V binding in 
double fluorescence with CD45. Values measured for each cell line are reported as box plots. Differences (p-values) are shown (N=6). 
(C) Graphical representation of cell death values of PBMC no CC or cocultured for 6 h with D54, U251 and SF767 glioblastoma cells, 
previously silenced or not for PD-L1. PBMC was harvested and assayed by flow cytometry. Values are reported as box plots. Differences 
are shown (N=6).
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melanoma, in which FKBP51s was upregulated by contact 
with lymphocytes [16], this spliced isoform appeared to be 
constitutively expressed in glioblastoma cell lines at high 
levels. Our results show that, in glioma cells, FKBP51s is 
complexed with PD-L1 in the ER and its down modulation 
decreased the level glycosylated-PD-L1, suggesting that 
the isomerase activity of FKBP51s was relevant for PD-
L1 folding and processing. It is worth noting that post-
translational modifications of surface receptor/ligand 
antigens greatly influence the affinity for the cognate 
molecules. In particular, PD-L1 has an affinity for PD1 
of 0.77 μM when glycosylated and in dimers, while the 
monomeric nonglycosylated protein has an affinity of 26.6 
μM [15]. In accordance with its proposed role as a PD-
L1 foldase, use of selective inhibitors of FKBP51 PPIase 
activity significantly down modulated PD-L1 expression. 
Most interestingly, SAFit2 was able to counteract the 
increase in PD-L1 levels in glioblastoma cells treated with 
IR. This result might have an impact in clinical practice, 
considering that combining IR and anti-PD-L1 treatment 
led to tumour regression and prevented the growth of 
secondary tumours in a mouse tumour xenograft model 
[38]. Given the above findings, FKBP51s may contribute 
to an efficient inhibitory checkpoint signal, and thus to 
glioma-edited immune suppression. Consistent with 
such a hypothesis, the addition of SAFit to co-cultures of 
PBMCs and glioma cells reduced apoptosis of immune 
cells induced through PD-L1/PD1. Future in vivo 
studies with syngeneic mouse models are now needed 
to validate the efficacy of selective FKBP51 inhibitors 
in modulating tumour PD-L1 expression and, most 
importantly, to verify whether these small molecules are 
able to positively affect tumour microenvironment and 
ameliorate immune defences against glioma. Besides the 
tumour, immune accessory cells in the microenvironment 
can express PD-L1 and suppress CD8-mediated tumour 
killing. Particularly, in glioblastomas, a very recent 
study [39] identified a tumour-infiltrating myeloid cell 
(TIM) population that expands in response to dendritic 
cell vaccine treatment and greatly contributes to PD-L1 
expression in the glioblastoma environment. Whether 
or not this TIM expresses FKBP51s is unknown. 
Interestingly, we identified a myeloid-derived suppressor 
cell CD14+PD-L1+FKBP51s+ in peripheral blood of 
melanoma patients, expressing high TGF-β levels and 
apparently associated with resistance to ipilimumab 
[40]. Immunohistochemistry of FKBP51s performed on 
29 tumoral samples showed an expression pattern (with 
either a nuclear and cytoplasmic localization) similar to 
that observed in cancer cell lines, thus reinforcing the 
translational implication of our findings. Regarding PD-
L1 expression, in our series, the majority of cases showed 
a cytoplasmic pattern of reactivity, while a membranous 
signal was faintly evident only in a few tumour cells 
showing epithelioid morphologic features, as it was 
previously observed [3]. A possible explanation for this 
diffuse/fibrillary cytoplasmic pattern has been attributed 
to the membrane-bound PD-L1, within the delicate tumour 
Figure 6: FKBP51s and PD-L1 immunohistochemistry of glioblastoma samples. Case #28, (A) hematoxylin and eosin staining; 
(B) anti-GFAP; (C) diffuse/fibrillary cytoplasmic PDL1 expression with a membranous signal in more than 5% of neoplastic cells. Original 
magnification x400. (D, E, F) FKBP51 immunostaining: cytoplasmic signal was strong, moderate and mild in case #12 (D), #14 (E) and 
#19 (F), respectively. In the nucleus, the reactivity was moderate in case #12 (D) and case #19 (F) and strong in case #14 (E). Original 
magnification x400. (G) box plots of FKBP51s scores (c=cytoplasmic and n=nuclear) in PD-L1low and PD-L1high expressing glioblastomas. 
(H) quantitative FKBP51s expression of 8 glioblastoma samples. QPCR was performed by using a coamplified β-actin internal control for 
sample normalization. FKBP51s value of a PBMC has been also run for comparison. Columns and bars are representative of means and 
standard deviations of values for each sample as individual data point.
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cell process forming the pathognomic neurofibrillary 
matrix of gliomas [3]. Interestingly, we found that the 
scores of FKBP51s tended to be increased in accordance 
with PD-L1 scores, which generates the hypothesis (to be 
addressed with a larger sample size) that the two variables 
(FKBP51s and PD-L1) might be associated. We observed 
that 6 out of 22 PD-L1 positive tumour samples expressed 
only nuclear FKBP51s, which is in disagreement with our 
finding that the PD-L1 maturation occurs in the ER. An 
active FKBP51s shuttling within cell compartments, to 
convey information on nuclear and cytoplasmic activities, 
as it occurs for several proteins [41], might explain this 
result. Currently, the biological significance for the 
proposed shuttling, as well as the function of FKBP51s 
inside the nucleus, remain obscure.
Given the above, we propose that FKBP51s is 
a novel element that regulates PD-L1 expression in 
glioma cells. This co-chaperone functions as a catalyst 
and foldase in PD-L1 post-translational modifications, 
occurring during protein maturation and expression on 
the plasma membrane. In vitro inhibition of this protein, 
either by silencing or chemical agent results in PD-
L1 down modulation in glioblastoma cells lines and, 
as a consequence, the suppressive effect exerted by the 
tumour on immune cells is relieved. Moreover, targeting 
of FKBP51s counteracts the PD-L1-increasing effect 
of ionizing radiation. Our findings on patient tumours 
show that the spliced FKBP51 is widely expressed 
in glioblastomas. It is worth noting that factors other 
than FKBP51s control the expression of PD-L1 at the 
transcriptional and translational level. Nevertheless, this 
foldase appears to be important for PD-L1 glycosylation, 
which increases the affinity for its cognate molecule PD1 
[15]. It is noticeable that even if targeting the PD1/PD-
L1 inhibitory checkpoint is, to date, the most effective 
immunotherapy used in the treatment of cancers, 
primary resistance occurs in almost 60% of patients 
[42]. In addition, a proportion of the responder patients 
develop acquired resistance. In general, very little is 
known about the mechanisms of resistance. A number 
of factors account for primary resistance, such as poor 
tumour immunogenicity, limited intra-tumoral T-cell 
infiltration, defective antigen presentation and naive T-cell 
priming [42]. The release of adenosine or indoleamine 
2,3-dioxygenase in the microenvironment or mutations 
of the genes encoding JAK1 or JAK2 (key intracellular 
signalling mediating tumour sensitivity to interferon) 
or the gene encoding β-2-microglobulin (involved in 
folding and transport of MHC class I molecules) are 
recognized causes of acquired resistance [42]. We do 
not have sufficient knowledge on the spliced FKBP51 
to speculate on potential effects of its inhibitors on 
circumventing resistance to anti-PD1. Our data support 
the conclusion that SAFit acts in the same direction of 
immune checkpoint blockade (i.e., contrasting PD-L1). 
In this view, used in combination, SAFit can reduce both 
the doses and side effects of the immunomodulatory 
treatment. In addition, a previous study on melanoma 
[30] showed that SAFit efficiently suppresses the pro-
oncogenic activity of canonical FKBP51, namely NF-κB 
transcription factor activation and cyclin D upregulation. 
Other authors have identified that canonical FKBP51 
exerts a relevant role in glioma aggressiveness [24]. Based 
on these considerations, SAFit could, at the same time, 
contrast some autonomous tumour cell functions and PD-
L1-mediated T-cell impairment, in glioma tumours, thus 
integrating two important approaches for cancer treatment. 
Future studies will address this hypothesis. Finally, 
the low molecular weight of SAFit allows the agent to 
penetrate through the brain barrier, which is an important 
requirement for drugs candidate to glioma treatment [26]. 
In conclusion, our finding provides the basis for a novel 
molecular player in glioma immune evasion. In vivo 
studies with a syngeneic mouse glioma model are needed 
to confirm that FKBP51s is a useful target for control of 
glioma immune evasion, thus offering a new tool in the 
immunotherapy armamentarium against cancer.
MATERIALS AND METHODS
Cell culture and transfection
Human glioma cell lines D54 and U251, from the 
CEINGE cell bank (Cellular Technology Platform) at 
the Advanced Biotechnology Institute (Naples, Italy), 
were cultured at 37°C and 5% CO2 in DMEM-F12 
media (Biowest, Nuaillé, France) containing 10% foetal 
bovine serum (FBS; Biowest). In accordance with 
the international guidelines established by the United 
Kingdom Coordination Committee on Cancer Research 
(UKCCCR) for the good use of continued cell lines, the 
cell bank of CEINGE guarantees cell lines for identity, 
cross-contamination and microorganism contamination. 
Pluripotent Stem Cells (iPSC, iPS DF19-9-7T; WiCell, 
Madison, WI, USA) were grown on Matrigel (BD 
Biosciences) coated dishes in mTeSR1 medium (Stem 
Cell Technologies). Human glioma cell line SF767 
was kindly provided by Prof. Gerolama Condorelli 
(University of Naples, Federico II) and cultured at 37°C 
and 5% CO2 in DMEM medium (Biowest, Nuaillé, 
France) containing 5% foetal bovine serum (FBS; 
Biowest). Human melanoma cell lines SAN and A375 
were obtained and cultured as previously described 
[21]. All cell lines used are mycoplasma free. To create 
FKBP51s overexpressing glioma cells, a True-ORF-
Myc-DDK-tagged expression vector was used (OriGene 
Technologies, Rockville, MD, USA). This vector carried 
the cDNA of the human FKBP5 transcript variant 4. 
The relative void vector was also transfected to generate 
control cells. Transfection was performed using a K2 
Transfection System (Biontex, Munich, Germany), 
according to the manufacturer’s recommendations. For 
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knockdown experiments, cells were transfected with 
specific short-interfering oligoribonucleotide (siRNA) 
(or with a nonsilencing oligoribonucleotide [NS RNA] as 
control) at a final concentration of 50 nM using the K2 
Transfection System. NS RNA and siRNA for PD-L1 were 
purchased from Novus Biological (Littleton, CO, USA). 
For FKBP51s siRNA, siRNA #1 and #2 were synthesized 
using target sequences at the 3′-coding region (between 
700 and 1100 bp). In addition to siRNA #1 and #2, the 
siRNA mix contained siRNA #3 (target sequence in the 
3′-UTR region, of between 5200 and 5800 bp). Twenty-
four hours before transfection, cells were seeded into six-
well plates at a concentration of 4 × 105 cells/ml to obtain 
80–90% confluence at the time of transfection. Cells were 
treated 24 h after transfection. A 6 MV X-ray of a linear 
accelerator (Primus, Siemens, München, Deutschland) was 
used for the ionizing radiation (IR) experiments. Selective 
inhibitors of the FK506-binding protein 51 by induced fit 
(SAFits) were from the laboratory of Prof. Felix Hausch 
[21]. The anti-PD1 used in the co-cultures was nivolumab 
(BMS-936558; Bristol-Myers Squibb, Princeton, NJ, 
USA). For experiments with SAFit compounds (50 μM in 
DMSO stock solution), 1:1000 DMSO:DMEM-F12 media 
was used for control cells.
Immunoblot and immunoprecipitation
Whole cell lysates were homogenized in modified 
RIPA buffer [15] and assayed by immunoblot. The primary 
antibody against FKBP51s (rabbit polyclonal of our 
production, raised against protein C-terminus), CD274/
PD-L1 (rabbit polyclonal; Novus Biological) and FKBP51 
(rabbit polyclonal; Novus Biologicals) were used diluted 
1:2500. For PD-L1 detection, a further rabbit polyclonal 
antibody Pdcd-1L1 (H-130; Santa Cruz Biotechnology, 
CA, USA) was used diluted 1:1000. The M2-Flag 
(mouse monoclonal; Sigma-Aldrich, St. Louis, MO, 
USA) and γ-tubulin (mouse monoclonal; Sigma-Aldrich) 
antibodies were used diluted 1:5000. Anti-G3PDH (rabbit 
monoclonal; Cell Signalling, Danvers, MA, USA) was 
used at 1:1000. Anti-TGN46 (1:1000; rabbit polyclonal 
antibody; Sigma-Aldrich); anti-Calnexin (1:1000; AF18, 
mouse monoclonal; Invitrogen, Carlsbad, CA, USA) and 
anti-Histone H1 (1:500; AE-4, mouse monoclonal; Santa 
Cruz Biotechnology) were used as Trans Golgi Network 
(TGN), endoplasmic reticulum (ER) and nucleus markers, 
respectively. For co-immunoprecipitation, D54 was used 
for endogenous pull-down of PD-L1 and FKBP51s. Five-
hundred micrograms of total lysate was pre-cleared for 1 h 
at 4°C, with rotation. Then, 1 μg of each specific antibody 
was added to the lysate and kept in rotation at 4°C 
overnight. Twenty microliters of the Protein A-Agarose 
(Santa Cruz) was added to the mixture and precipitation 
took place for 2 h, with rotation at 4°C. Samples were then 
washed in modified RIPA buffer and separated by SDS-
PAGE. PD-L1 and FKBP51s antibodies were recognized 
by immunoblot.
Immunostaining and microscopy
D54 and U251 were fixed in 4% paraformaldehyde 
and permeabilized with 0.2% Triton X-100 in 1× PBS for 
5 min at room temperature. The non-specific block was 
performed by treating cells with 10% FBS (Biowest), 
1% BSA (Biorad), 0.1% in PBS for 30 min at room 
temperature. Then, the samples were incubated with 
primary and secondary antibodies. Rabbit polyclonal, 
FKBP51s and FKBP51 primary antibodies (see 
Immunoblot and immunoprecipitation section) were used 
at 1:2000 and 1:50 dilutions, respectively. Alexa Fluor 594 
or 488 secondary antibodies were used (1:400; Invitrogen). 
Nuclei were counterstained with DAPI (Calbiochem-
EMD Biosciences, 1:5000). Images were captured with 
an inverted microscope (DMI4000; Leica Microsystems, 
Heidelberg, Germany) with Leica Application Suite 
Advanced Fluorescence (LASAF) software (Leica 
Microsystems). When required, the brightness, contrast 
and colour balance of the images were adjusted in 
Photoshop CS2 (Adobe Systems, San Jose, CA, USA). 
This adjustment was applied to every pixel in each image.
Glycosidase digestion
Lysates from D54 cells were subjected to PD-L1 
immunoprecipitation. Briefly, 500 μg of total lysate were 
incubated with 800 ng of anti-PD-L1, or rabbit control 
IgG (rabbit polyclonal; Santa Cruz Biotechnology), and 
kept in rotation at 4°C overnight. After 24 h, 20 μl of 
Protein A-Agarose (Santa Cruz) was added to the mixture 
and precipitation took place for 2 h, at 4°C in rotation. 
Samples were then washed thrice in modified RIPA buffer 
and resuspended in appropriate glycosidase buffer. The 
N-Glycosidase F (PGNase F) digestion was performed 
according to the manufacturer’s instructions (CalBiochem 
Deglycosylation Kit, Merck Millipore, Temecula, CA) 
to allow N-linked oligosaccharides cleavage of PD-L1, 
in native conditions. Digested samples were analysed by 
immunoblot.
Sub-cellular fractionation
Fractionation was performed according to 
Sarnataro et al. [28], with little modifications. Briefly, 
D54 glioblastoma cells were homogenized in 800 μl of 
Buffer F (0.25 M sucrose, 10 mM HEPES-NaOH, pH 7.2, 
10 mM KAc, 1.5 mM MgAc) by pipetting the solution 
up and down 8–10 times through a 22-gauge needle. The 
nuclear fraction was sedimented by centrifugation for 5 
min at 600×g and then resuspended in RIPA modified 
buffer. The post-nuclear supernatant was adjusted to 
0.75 M sucrose, and the ER fraction was sedimented by 
ultracentrifugation for 12 min at 16,000 rpm at 4°C, in 
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a Beckman with an SW 50.1 Ti rotor and resuspended in 
RIPA modified buffer. The supernatant, containing ER 
fraction, was subjected to immunoprecipitation for PD-
L1 as above described. Immunoprecipitated fractions and 
relative fractionated lysates were analysed by immunoblot 
(see Immunoblot and immunoprecipitation section for 
antibodies specification).
qPCR
Serial sections of 10 μm from routinely Formalin-
fixed, paraffin-embedded blocks were cut, and total RNA 
was isolated from eight paraffinized tumours, chosen 
among those analysed by IHC, by using the High Pure 
RNA Paraffin Kit (Sigma) according to the manufacturer’s 
instructions. One microgram of each RNA was used for 
cDNA synthesis with iScriptTM Reverse Transcription 
(Bio-Rad, CA, USA). Quantitative gene expression was 
quantified by qPCR with the 2-ΔCT comparative method 
[29], using the SsoAdvancedTM SYBR Green Supermix 
(Bio-Rad) and specific qPCR primers to analyse each 
transcript. To detect FKBP51, validated QuantiTec primers 
from Qiagen (Valencia, CA, USA) were used. Relative 
quantitation of the transcript was performed using co-
amplified ribosomal 18S [16] and β-Actin [30] as internal 
controls for normalization.
Co-cultures of glioblastoma cells and peripheral 
blood mononuclear cells (PBMCs)
Co-culture was performed as described previously 
[16]. Briefly, 24 h before starting the co-culture, D54 
glioblastoma cells were plated at a concentration of 4 × 
105 cells/35 mm plate. After initial plating, the culture 
medium was aspirated, and adherent cells were washed 
three times. PBMCs, isolated from heparinized blood by 
a Ficoll-Hypaque density gradient, were collected and 
washed by centrifugation. PBMCs were pre-activated 
with anti-CD3 (eBioscience, San Diego, CA, USA) at the 
concentration of 5 μg/ml. After 16 h, PBMCs were washed 
and resuspended in 1% FBS RPMI-1640 medium (Lonza, 
Belgium) at 1 × 106/ml and 2 ml suspension was added 
into each glioma cells-precoated plate. Cells were co-
cultured at 37°C in a 5% CO2 humidified atmosphere in the 
presence of anti-PD1 (5 μg/ml) or Abciximab (5 μg/ml). 
For co-culture with SAFit, glioma cells were preincubated 
with SAFit1 (40 nM) or SAFit2 (60 nM) for 12 h before 
adding PBMC. For co-culture with PD-L1 silencing, 
glioma cells were transfected as described in the Cell 
culture and transfection section and, after 24 h, PBMC 
suspension was added to each glioma cell-precoated plate. 
After 6 h of co-culture, cells in suspension were collected 
and separated by centrifugation of supernatants. In each 
experiment, PBMC was also maintained in mono-cultures 
as a control. PBMC apoptosis was assayed by flow 
cytometry.
Flow cytometry
Expression of PD-L1 was assessed using anti-
B7H1-phycoerythrin (PE) (R&D Systems, Minneapolis, 
MN, USA) at a concentration of 0.05 μg/ml. A relative 
Ig isotype PE-conjugated antibody was used as a control 
of non-specific binding. Samples were analysed using a 
BD Accuri™ C6 Cytometer (BD Biosciences, New Jersey, 
USA). Analysis of apoptosis was performed by annexin-V 
staining in double fluorescence with CD45-Peridinin 
Chlorophyll Protein Complex (PerCP) conjugated. Briefly, 
1 × 105 cells were harvested 6 h after co-culture (see co-
culture paragraph) and resuspended in 100 μl of binding 
buffer (10 μM Hepes/NaOH pH 7.5, 140 μM NaCl, 
and 2.5 μM CaCl2) containing 1 μl of annexin-V-FITC 
(Pharmingen/Becton Dickinson, San Diego, CA, USA) 
and 5 μl of CD45 for 15 min at room temperature in the 
dark. Then, 100 μl of the same buffer was added to each 
sample and analysed with BD Accuri™ C6 Cytometer 
(BD Biosciences).
Immunohistochemistry
Tissues were formalin fixed and paraffin 
embedded. For each case, the most representative block 
was selected, and two 4 μm thick sections were cut to 
perform immunohistochemical staining with the anti-
FKBP51s primary antibody (see the Immunoblot and 
immunoprecipitation section) at a 1:100 dilution and anti-
PD-L1 (Novus; see Immunoblot and immunoprecipitation 
section) at a 1:200 dilution. Sections were dewaxed 
in xylene, hydrated in a graded series of alcohol and 
subjected to heat-induced antigen retrieval. After blocking 
endogenous peroxidase activity, the tissue was incubated 
with anti-FKBP51s for 60 min and anti-PD-L1 overnight. 
Subsequently, the slices were rinsed and incubated with the 
biotinylated secondary antibody at room temperature for 
30 min. The bound antibody complexes were stained for 
3–5 min, or until appropriate, for microscopic examination 
with diaminobenzidine, and then counterstained with 
hematoxylin (30 s) and mounted. Appropriate positive 
controls for each staining were chosen: normal skin tissue, 
comprehensive of appendages, for FKBP51s and normal 
placental tissue for PD-L1. Negative controls were given 
by sections of glioblastomas treated only with the antibody 
diluent. The expression of both proteins (FKBP51 and 
PD-L1) was recorded according to their localization in the 
cells. Afterwards, a score was established as the product 
of a proportion score (1: ≤10%; 2: >10% and <50%; 3: 
≥50% of tumour cells) and an intensity score (1.weak: the 
signal was evident only at 40× magnification; 2.moderate: 
the signal was evident at 20× magnification; 3.strong: the 
signal was evident at 10× magnification). The presence 
of epithelioid tumour cells showing a distinct PD-L1 
membranous signal was recorded only if they represented 
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≥5% of all tumour cells (in accordance with the cut-off 
used a previous publication) [31].
Statistical analysis
Student’s t-test was used to analyse differences 
between means of values. ANOVA served to compare 
different experimental groups. A p-value of ≤ 0.05 was 
considered statistically significant.
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